A novel rapid (20-minute) IL-6 release assay using blood mononuclear cells of patients with various clinical forms of drug induced skin injuries

World Allergy Organization Journal

Sándor Sipka¹  Susan Lakatos²  Katalin Schweitzer²  Joseph M Baló-Banga³ 

[1] Division of Clinical Immunology, University of Debrecen, Móricz Zs. u. 22, Debrecen 4032, Hungary;Department of Pathophysiology, Medical Center of Hungarian Defense Forces, Róbert Károly krt. 44, Budapest H-1134, Hungary;Department of Dermatology, Medical Center of Hungarian Defense Forces, Podmaniczky u. 109-111, Budapest H-1062, Hungary

关键词: Preformed cytokines’ release;    Adverse drug reactions;    Drug-induced skin injury;    T-lymphocytes;    TNF-alpha;    IL-6;   

Others  :  1137523
DOI  :  10.1186/1939-4551-8-1

 received in 2013-03-15, accepted in 2014-11-03,  发布年份 2015

【 摘 要 】

Background

IL-6 is a pro-inflammatory cytokine which has many well-defined effects. Its synthesis and release from mononuclear cells of drug-sensitized patients was related before to in vitro drug-allergy diagnostics but has not yet been studied in detail.

Methods

The specific release of preformed IL-6 from peripheral blood mononuclear cells (PBMC) after 20 minutes incubation with 0.15–0.5 μM of pure drugs was measured in two groups of drug-allergy suspected donors (159) and respective controls (48). IL-6, TNF-alpha, IL-2, IL-4, IFN-gamma have been measured from cell supernatants by ELISA or by cytometric bead assay. Epicutaneous, intradermal and systemic provocation tests were performed to prove or disprove culprit substances (203 in vivo against 482 in vitro tests). T-test (paired and unpaired); chi2 contingency table; Z statistics and McNemar’s test were used to evaluate results.

Results

Concanavalin A as positive control released IL-6 from PBMC in linear concentration and exponential time dependent fashion (up to 60 minutes) pointing to the existence of a preformed pool of this cytokine.

Preformed IL-6 released at any of 4 standard drug dilutions tested, above 50% over their diluents’ levels significantly correlated with the patients’ history on drug-induced hypersensitivity symptoms and with in vivo tests.

Sensitivity of 85.4% and specificity of 82.4% of the IL-6 release assay were found. The 20′ drop in release of TNF-alpha had no diagnostic importance; it has accompanied increased IL-6 release. IL-2, IL-4 and IFN-gamma were undetectable in 20 minutes supernatants. IL-6 release depended on the clinical phenotype but not on the eliciting drug(s) in the molecular mass range of 76–4000 Da. Reactivity of mononuclear cells at the lowest or at multiple drug test concentrations reflected clinical severity per diagnoses and according to area of skin involvement.

Conclusion

This rapid test is applicable to detect a wide scale of drug hypersensitivity.

【 授权许可】

   
2015 Baló-Banga et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]De Sousa-Pinto JM, Babo MJ: In vitro diagnosis of drug allergy. Assessment of the Chromatin Activation Test (CAT). Pharmacoepidem Drug Safe 1997, 6(Suppl 3):861-869.
• [2]Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ: Drug specif ic in vitro release of IL-2, IL5, IL-13 and IFN-γ in patients with delayed type drug hypersensitivity. Allergy 2009, 64:1269-1278.
• [3]Hausmann O, Schnyder B, Pichler WJ: Drug hypersensitivity reactions involving skin. Handb Exp Pharmacol 2010, 196:29-55.
• [4]Pichler WJ: Delayed drug hypersensitivity reactions. Ann Intern Med 2003, 139:683-693.
• [5]Halevy S, Cohen AD, Grossmann N: Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymphocytes in cutaneous adverse drug reactions. J Am Acad Dermatol 2005, 52:254-261.
• [6]Merk HF: Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines. Toxicology 2005, 209:217-220.
• [7]Holub MC, Makó E, Dévay T, Dank M, Szalai C, Fenyvesi A, Falus A: Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Scand J Gastroenterol 1998, 228:47-50.
• [8]Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulations. Biochem J 2003, 374:1-20.
• [9]Baló-Banga JM, Barabás É, Merétey K: Chromatin changes and adverse drug reactions. Central East Eur Derm-Venereol Assoc (CEEDVA) Bulletin 2003, 5:4-14.
• [10]Baló-Banga JM: New in vitro cytokine release tests for in vitro diagnosis of drug allergies [abstract]. J Eur Acad Derm Vener 2004, 18(Suppl 2):55.
• [11]Spencer LA, Szela CT, Perez SA, Kirchhoffer CL, Neves JS, Radke AL, Weller PF: Human eosinophils constitutively express multiple Th1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol 2009, 85:117-123.
• [12]Sancho-Serra Mdel C, Simarro M, Castells MC: Rapid IgE desensitization is antigen specific and impaired early and late mast cell responses targeting FcϵRI internalization. Eur J Immunol 2011, 41:1004-1013.
• [13]Karch FE, Lasagna L: Toward the operational identification of adverse drug reactions. Clin Pharmacol Therap 1977, 21:247-254.
• [14]Bøyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 1968, 21(Suppl 97):77-89.
• [15]Dulbecco R, Vogt M: Plaque formation and isolation of pure cell lines with poliomyelitis viruses. J Exp Med 1954, 99:167-182.
• [16]Brailly H, Montero-Julian FA, Zuber CE, Flavetta S, Grassi J, Houssiau F, vanSnick J: Total interleukin-6 in plasma measured by immunoassay. Clin Chem 1994, 40:116-123.
• [17]Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003, 58:854-863.
• [18]Tabakov VU, Litvina MM, Schepkina JV, Jarilin AA, Chestkov VV: Studying the proliferation of human peripheral blood T lymphocytes in serum-free medium. Bull Exp Biol Med 2009, 147:120-124.
• [19]McHugh SM, Wilson AB, Deighton J, Lachmann PJ, Ewan PW: The profiles of interleukin (IL)-2, IL-6, and interferon-gamma production by peripheral blood mononuclear cells from house dust-mite allergic patients: a role for IL-6 in allergic disease. Allergy 1994, 49:751-759.
• [20]Beeler A, Zaccaria L, Kawataba T, Gerber BO, Pichler WJ: CD69 upregulation on T cells as an in vitro marker for delayed type drug hypersensitivity. Allergy 2008, 63:181-188.
• [21]Mockenhaupt M: Epidemiology of cutaneous adverse drug reactions. In Adverse Cutaneous Drug Eruptions. Edited by French LE. Basel: Karger; 2012:1-17. [Chem Immunol Allergy, vol 97.]
• [22]Pirmohamed M, Friedman PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton B, Papaluca-Amati M, Demoly P, Shear NH: Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011, 89:896-901.
• [23]Baló-Banga JM, Vajda A: Attempts to standardize intradermal drug tests based on molecular mass and on clinical phenotypes. Some pitfalls or exceptions? Clin Transl Allergy 2014, 4(Suppl 3):102. BioMed Central Full Text
• [24]Adam J, Eriksson KK, Schnyder B, Fontana S, Pichler WJ, Yerly D: Avidity determines T-cell reactivity in abacavir hypersensitivity. Eur J Immunol 2012, 42:1706-1716.
• [25]Hirata S, Hattori N, Kumagai K, Haruta Y, Yokoyama A, Kohno N: Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis. Clin Chim Acta 2009, 407:25-29.
• [26]Mori H, Yamanaka K, Kaketa M, Tamada K, Hakamada A, Isoda K, Jamanishi K, Mizutani H: Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. J Dermatol 2004, 31:731-736.
• [27]Jagicza A, Bata Z, Mihályi L, Kemény L, Kenderessy-Sz A, Schweitzer K, Baló-Banga JM: A case of heparine allergy. Bőrgyógy Vener Szemle [Hung] 2008, 84:76-79.
• [28]Krummel MF, Cahalan MD: The immunological synapse: a dynamic platform for local signaling. J Clin Immunol 2010, 30:364-372.
• [29]Jones SA, Richards PJ, Scheller J, Rose-John S: IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005, 25:241-253.
• [30]Igaz P, Horváth A, Horváth B, Szalai C, Pállinger E, Rajnavölgyi E, Tóth S, Rose-John S, Falus A: Soluble interleukin-6 receptor (sIL-6R) makes IL-6 negative T cell line respond to IL-6; it inhibits TNF production. Immunol Lett 2000, 71:143-148.
• [31]Tilg H, Trehu E, Atkins MB, et al.: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble Tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
• [32]Réthy LA, Baló-Banga JM: Drugs as haptens induce apoptosis in lymphocytes from patients with drug-allergies. In Proc. 14th European Immunology Meeting (EFIS 2000). Edited by Mackiewicz A, Kurpisz M, Zeromski J. Bologna: Monduzzi Editore S.p.A; 2001:105-112.